The aim of the project is to develop a non-invasive method to detect breast cancer early and identify of specific molecular subtypes through metabolomics and miRNA analysis in liquid biopsies. These new methods will help to establish the optimal individualised therapy and predict treatment response in breast cancer patients.

The starting hypothesis is based on the existence of alterations in normal metabolic processes that occur in cancer cells and do not occur in healthy cells. This leads to changes in the normal serum concentrations of certain metabolites that can be easily detected and analysed through blood samples.